Carfilzomib, Dexamethasone, and Daratumumab (KdD) vs Kd: subgroup analysis of the CANDOR study by prior autologous stem cell transplantation, Lenalidomide exposure, or Lenalidomide refractory disease

被引：0
|
作者：
Mateos, Maria-Victoria [1 ]
Usmani, Saad Z. [2 ]
Quach, Hang [3 ]
Dimopoulos, Meletios-Athanasios [4 ]
Fonseca, Rafael [5 ]
McFadden, Ian [6 ]
Yusuf, Akeem [6 ]
Khurana, Monica [6 ]
Obreja, Mihaela [6 ]
Spencer, Andrew [7 ]
机构：
[1] Univ Hosp Salamanca, Inst Canc Mol & Cellular Biol, Salamanca, Spain
[2] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[3] Univ Melbourne, St Vincents Hosp, Melbourne, Vic, Australia
[4] Natl & Kapodistrian Univ Athens, Sch Med, Alexandra Gen Hosp, Dept Clin Therapeut, Athens, Greece
[5] Mayo Clin, Scottsdale, AZ USA
[6] Amgen Inc, Thousand Oaks, CA 91320 USA
[7] Monash Univ, Alfred Health, Clayton, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-204
引用
收藏
页码：S150 / S151
页数：2
相关论文
共 50 条
  • [41] MajesTEC-7: A Phase 3, Randomized Study of Teclistamab plus Daratumumab plus Lenalidomide (Tec-DR) Versus Daratumumab plus Lenalidomide plus Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant
    Krishnan, Amrita Y.
    Manier, Salomon
    Terpos, Evangelos
    Usmani, Saad
    Khan, Josephine
    Pearson, Rachel
    Girgis, Suzette
    Guo, Yue
    McAleer, Dana
    Olyslager, Yunsi
    Kampfenkel, Tobias
    van de Donk, Niels W. C. J.
    BLOOD, 2022, 140 : 10148 - 10149
  • [42] Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd
    Raje, Noopur S.
    Vij, Ravi
    Reece, Donna
    Berdeja, Jesus G.
    Stephens, Leonor A.
    McDonnell, Kathryn
    Rosenbaum, Cara A.
    Jasielec, Jagoda
    Richardson, Paul G.
    Gurbuxani, Sandeep
    Nam, Jennifer
    Severson, Erica
    Wolfe, Brittany D.
    Rosebeck, Shaun
    Stefka, Andrew
    Dytfeld, Dominik
    Griffith, Kent
    Jakubowiak, Andrzej
    BLOOD, 2016, 128 (22)
  • [43] Frontline Therapy with Bortezomib, Lenalidomide, and Dexamethasone (VRD) Induction Followed by Autologous Stem Cell Transplantation, VRD Consolidation and Lenalidomide Maintenance In Newly Diagnosed Multiple Myeloma Patients: Primary Results of the IFM 2008 Phase II Study
    Roussel, Murielle
    Avet-Loiseau, Herve
    Moreau, Philippe
    Huynh, Anne
    Benboubker, Lotfi
    Hulin, Cyrille
    Marit, Gerald
    Leleu, Xavier
    Pegourie, Brigitte
    Fruchart, Christophe
    Caillot, Denis
    Stoppa, Anne-Marie
    Facon, Thierry
    Harousseau, Jean-Luc
    Attal, Michel
    BLOOD, 2010, 116 (21) : 274 - 275
  • [44] Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma
    Trneny, Marek
    Lamy, Thierry
    Walewski, Jan Andrzej
    Belada, David
    Mayer, Jiri
    Radford, John A.
    Jurczak, Wojciech
    Morschhauser, Franck
    Alexeeva, Julia
    Rule, Simon
    Biyukov, Tsvetan Nikolov
    Patturajan, Meera
    Bravo, Marie-Laure Casadebaig
    Cabecadas, Jose
    Arcaini, Luca
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] IMPACT OF PRIOR TREATMENT ON PFS FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA PATIENTS RANDOMIZED TO LENALIDOMIDE VS INVESTIGATOR'S CHOICE: A SUBGROUP ANALYSIS OF THE PHASE II MCL-002 (SPRINT) STUDY
    Trneny, M.
    Lamy, T.
    Walewski, J.
    Belada, D.
    Mayer, J.
    Radford, J.
    Jurczak, W.
    Morschhauser, F.
    Alexeeva, J.
    Rule, S.
    Biyukov, T.
    Patturajan, M.
    Bravo, M. L. Casadebaig
    Arcaini, L.
    HAEMATOLOGICA, 2015, 100 : 4 - 4
  • [46] Leopard: A Phase II Study of Maintenance Lenalidomide and Prednisolone Post Autologous Stem Cell Transplantation (ASCT) for Myeloma, Incorporating Minimal Residual Disease Assessments
    Kalff, Anna
    Kennedy, Nola
    Walker, Patricia A.
    Khong, Tiffany T.
    Schwarer, Anthony
    Roberts, Andrew W.
    Campbell, Philip
    Filshie, Robin
    Smiley, Angela
    Gorniak, Malgorzata
    Black, Marion
    Jenkins, Nicole
    Raines, Geoffrey
    Spencer, Andrew
    BLOOD, 2014, 124 (21)
  • [47] Bortezomib, Lenalidomide and Dexamethasone (VRD-GEM) As Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM): Results of a Prospective Phase III Pethema/GEM Trial
    Rosinol, Laura
    Oriol, Albert
    Rios, Rafael
    Sureda, Anna
    Blanchard, M. Jesus
    Hernandez, Miguel T.
    Martinez-Martinez, Rafael
    Moraleda, Jose M.
    Jarque, Isidro
    Bargay, Juan
    Gironella, Mercedes
    Moreno, Maria Jose
    Palomera, Luis
    Gonzalez-Montes, Yolanda
    Marti, Josep M.
    Krsnik, Isabel
    Arguinano, Jose M.
    Gonzalez, Maria Esther
    Gonzalez, Ana Pilar
    Casado, Felipe
    Lopez-Anglada, Lucia
    Paiva, Bruno
    Mateos, Maria-Victoria
    San Miguel, Jesus F.
    Lahuerta, Juan-Jose
    Blade, Joan
    BLOOD, 2017, 130
  • [48] Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
    Costa, Luciano J.
    Chhabra, Saurabh
    Godby, Kelly N.
    Medvedova, Eva
    Cornell, Robert F.
    Hall, Aric C.
    Silbermann, Rebecca W.
    Innis-Shelton, Racquel
    Dhakal, Binod
    DeIdiaquez, Diego
    Hardwick, Pamela
    Biru, Yelak
    Omel, James L.
    Hari, Parameswaran
    Callander, Natalie Scott
    BLOOD, 2019, 134
  • [49] Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
    Kumar, Shaji K.
    Jacobus, Susanna J.
    Cohen, Adam D.
    Weiss, Matthias
    Callander, Natalie
    Singh, Avina K.
    Parker, Terri L.
    Menter, Alexander
    Yang, Xuezhong
    Parsons, Benjamin
    Kumar, Pankaj
    Kapoor, Prashant
    Rosenberg, Aaron
    Zonder, Jeffrey A.
    Faber, Edward, Jr.
    Lonial, Sagar
    Anderson, Kenneth C.
    Richardson, Paul G.
    Orlowski, Robert Z.
    Wagner, Lynne, I
    Rajkumar, S. Vincent
    LANCET ONCOLOGY, 2020, 21 (10): : 1317 - 1330
  • [50] Phase 2 randomized study of daratumumab (dara), lenalidomide (R), bortezomib (V), and dexamethasone (d; Dara-RVd) vs. RVd in patients (pts) with newly diagnosed multiple myeloma (MM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT)
    Lin, T.
    Hydutsky, L.
    Parros, H.
    Murphy, S.
    Pei, H.
    Londhe, A.
    Ukropec, J.
    Qi, M.
    Lutska, Y.
    Sharma, M.
    ANNALS OF ONCOLOGY, 2017, 28
12345